Liraglutide: The Daily GLP-1 That Preceded Semaglutide
A once-daily GLP-1 receptor agonist — the class predecessor to semaglutide and tirzepatide, still widely prescribed under Victoza and Saxenda.
What is Liraglutide?
Liraglutide is a GLP-1 receptor agonist with 97% sequence homology to human GLP-1, modified with a fatty-acid side chain for albumin binding and extended action. Unlike the once-weekly semaglutide and tirzepatide, liraglutide requires once-daily subcutaneous dosing, titrated slowly upward to limit gastrointestinal side effects. It's FDA-approved under two brand names: Victoza for type 2 diabetes and Saxenda for chronic weight management, each with its own titration schedule and maximum dose. As an older, well-characterized GLP-1, it has the longest real-world safety record of any compound in this class.
Quick facts
- Molecular Formula
- C172H265N43O51
- Molecular Weight
- 3751.2 g/mol
- CAS Number
- 204656-20-2
- Half-Life
- ~13 hours
- Class
- GLP-1 receptor agonist (fatty-acid acylated peptide)
- Brand Names
- Victoza, Saxenda
- Legal Status
- Prescription-only, FDA-approved
- Category
- Metabolic / Weight Loss
- Storage
- Refrigerate at 2-8°C, protected from light. Do not freeze.
Dosing at a glance
Doses shown are those reported in published research, not a recommendation.
Liraglutide Mechanism of Action
GLP-1 Receptor Agonism
Liraglutide activates GLP-1 receptors throughout the body, sharing 97% sequence homology with native human GLP-1. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic satiety centers to reduce food intake. A C16 fatty-acid side chain attached via a glutamic-acid linker enables reversible albumin binding, protecting the peptide from DPP-4 degradation and extending its half-life to roughly 13 hours — far short of semaglutide's ~7 days, which is why liraglutide requires daily rather than weekly injections.
Two Brands, One Molecule
Liraglutide is sold under two FDA-approved brand names targeting different indications: Victoza (0.6–1.8mg daily) for type 2 diabetes glycemic control, and Saxenda (titrated up to 3.0mg daily) for chronic weight management in patients with obesity or overweight plus a weight-related comorbidity. The molecule is identical; only the approved indication, max dose, and packaging differ.
Liraglutide Dosage and Protocols
Titration Schedule
Both Victoza and Saxenda start at 0.6mg once daily subcutaneously for one week, then increase in 0.6mg increments at weekly-to-monthly intervals to limit nausea and GI upset. Victoza's typical maintenance dose is 1.2–1.8mg daily; Saxenda titrates further to a 3.0mg daily maintenance dose for weight management. Unlike semaglutide or tirzepatide, there is no weekly-injection version — liraglutide requires daily dosing for the life of the therapy, delivered via a pre-filled pen.
Liraglutide Side Effects and Safety
Common and Serious Risks
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, typically worst during dose titration. Boxed warning: risk of medullary thyroid carcinoma observed in rodent studies, which is why personal/family history of MTC or MEN 2 is an absolute contraindication. Other risks include pancreatitis, gallbladder disease, and (rarely) acute kidney injury secondary to dehydration from GI side effects. Pregnancy is contraindicated.
Liraglutide Research Evidence
Clinical Evidence Base
Liraglutide has the longest clinical track record of any GLP-1 receptor agonist, with over a decade of post-marketing safety data since Victoza's 2010 approval. The LEAD trial program established its glycemic efficacy in type 2 diabetes; the SCALE program established weight-loss efficacy (Saxenda, approved 2014), with average placebo-subtracted weight loss around 5–6% — modest compared to semaglutide or tirzepatide, reflecting its shorter half-life and lower peak systemic exposure.
Regulatory and Legal Status
Liraglutide is prescription-only and FDA-approved under both Victoza (type 2 diabetes) and Saxenda (chronic weight management) indications. It is a legitimate pharmaceutical, not a research chemical — it should only be obtained through a licensed prescriber and pharmacy. Off-label or self-directed use outside a prescribing relationship carries the same legal and safety concerns as any prescription-only medication.
Liraglutide Stacking and Combinations
Standalone Metabolic Therapy
Liraglutide is typically used as a standalone metabolic agent rather than stacked with growth or healing peptides. Clinicians occasionally combine it with resistance training and a higher-protein diet to offset lean-mass loss during a weight-loss course, but there is no established peptide-stacking protocol — unlike newer GLP-1s, it is rarely paired with GH secretagogues in research/clinic settings, largely because most patients on liraglutide are managed through standard endocrinology rather than peptide clinics.
Liraglutide Pharmacokinetics
Absorption and Clearance
Subcutaneous bioavailability is approximately 55%, with peak plasma concentration reached 8–12 hours after dosing. The fatty-acid albumin-binding mechanism slows both absorption and clearance, giving liraglutide its ~13-hour half-life — long enough for once-daily dosing but far shorter than the fatty-diacid modification used in semaglutide, which extends half-life to about 7 days. Steady state is reached within 4–5 days of consistent daily dosing.
Contraindications
- personal/family history of medullary thyroid carcinoma
- MEN 2
- pancreatitis
- pregnancy
Frequently asked questions
What is a typical Liraglutide dose?
Published research protocols report 0.6–3.0 mg, 1x daily (titrated). This is the range described in the literature, not a recommendation.
What is the half-life of Liraglutide?
~13 hours.
Is Liraglutide backed by strong evidence?
Liraglutide carries a REGEN research grade of S. REGEN Research Tier S — official FDA approval, on-label for the indications it is bought for.
How is Liraglutide administered?
Routes reported in the literature: subcutaneous.
Who should avoid Liraglutide?
Contraindications noted in the literature include personal/family history of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy.